DYRENIUM Drug Patent Profile
✉ Email this page to a colleague
When do Dyrenium patents expire, and what generic alternatives are available?
Dyrenium is a drug marketed by Concordia and is included in one NDA.
The generic ingredient in DYRENIUM is triamterene. There are seventeen drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the triamterene profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Dyrenium
A generic version of DYRENIUM was approved as triamterene by AGNITIO on August 19th, 2019.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for DYRENIUM?
- What are the global sales for DYRENIUM?
- What is Average Wholesale Price for DYRENIUM?
Summary for DYRENIUM
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 130 |
Patent Applications: | 4,273 |
Drug Prices: | Drug price information for DYRENIUM |
What excipients (inactive ingredients) are in DYRENIUM? | DYRENIUM excipients list |
DailyMed Link: | DYRENIUM at DailyMed |
Pharmacology for DYRENIUM
Drug Class | Potassium-sparing Diuretic |
Physiological Effect | Decreased Renal K+ Excretion Increased Diuresis |
US Patents and Regulatory Information for DYRENIUM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Concordia | DYRENIUM | triamterene | CAPSULE;ORAL | 013174-001 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Concordia | DYRENIUM | triamterene | CAPSULE;ORAL | 013174-002 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |